Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Ongoing save search
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.57 -1.72% -1.75% 560K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7446 -0.08% -0.08% 2.1M
|
Health Technology
|
| O: -48.62%
H: 5.38%
C: -7.69%
positive cancer ongoing tumor dna study
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Published: 2024-03-13 (Crawled : 15:00) - biospace.com/
SLN | $21.98 1.95% 1.91% 120K
|
Health Technology
|
| O: -5.02%
H: 5.71%
C: 4.11%
positive ongoing topline therapeutics study
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
APLT A | $4.74 -1.86% -1.9% 720K
|
Health Technology
|
| O: 17.54%
H: 21.59%
C: 19.05%
at-007 inspire positive ongoing trial therapeutics results
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
Published: 2023-12-20 (Crawled : 13:00) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 15.43%
H: 2.76%
C: -13.36%
positive update ongoing pharmaceuticals trial
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Published: 2023-12-19 (Crawled : 11:00) - globenewswire.com
TFFP | $3.2405 -9.69% 26K
|
Health Technology
|
| O: 17.75%
H: 0.0%
C: -22.4%
positive ongoing pharmaceuticals trials
Crinetics Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2023-12-18 (Crawled : 23:00) - crinetics.com
CRNX | $43.005 -2.28% -2.34% 540K
|
Health Technology
|
| O: 8.48%
H: 5.02%
C: 2.77%
positive treatment ongoing study
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2023-12-18 (Crawled : 21:00) - globenewswire.com
CRNX | $43.005 -2.28% -2.34% 540K
|
Health Technology
|
| O: 8.48%
H: 5.02%
C: 2.77%
positive treatment ongoing study
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.365 -4.64% -4.86% 470K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
STTK | $10.11 0.9% 0.89% 430K
|
Health Technology
|
| O: 107.58%
H: 23.74%
C: 10.96%
sl-1721 positive ongoing expansion topline trial
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Published: 2023-12-13 (Crawled : 11:00) - globenewswire.com
STTK | $10.11 0.9% 0.89% 430K
|
Health Technology
|
| O: 107.58%
H: 23.74%
C: 10.96%
sl-1721 positive ongoing expansion tp53 topline leukemia trial
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
COGT | $6.605 1.15% 1.14% 1.1M
|
Health Technology
|
| O: -50.35%
H: 6.99%
C: -5.36%
bezuclastinib positive ongoing trial advanced
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | News | $3.67 -3.42% -3.54% 320
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX 4 | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: 2.29%
H: 5.63%
C: -10.45%
conference vaccine breast positive cancer ongoing study
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Published: 2023-11-11 (Crawled : 20:20) - prnewswire.com
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
| Email alert
Add to watchlist
ion582 positive update ongoing trial
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
MOLN | News | $3.67 -3.42% -3.54% 320
|
Professional, Scientific, and T...
|
| O: 0.72%
H: 9.74%
C: 9.74%
mp0317 tumors positive ongoing meeting trial molecular
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Published: 2023-11-02 (Crawled : 15:30) - globenewswire.com
KRON | $1.01 -2.89% -2.97% 210K
|
Health Technology
|
| O: -0.18%
H: 13.95%
C: -4.93%
kb-0742 positive ongoing meeting study
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
KRON | $1.01 -2.89% -2.97% 210K
|
Health Technology
|
| O: 1.14%
H: 2.25%
C: -5.09%
kb-0742 positive ongoing meeting study
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
SEOVF | $0.3284 15.67% 2K
|
Health Technology
|
| O: 0.02%
H: 2.98%
C: -1.23%
congress positive cell ongoing trial diabetes
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.